## **Product** Data Sheet

## Namoline

Cat. No.: HY-115747 
CAS No.: 342795-11-3 
Molecular Formula:  $C_{10}H_3ClF_3NO_4$ 

Molecular Weight: 293.58

Target: Histone Demethylase

Pathway: Epigenetics

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	Namoline, a $\gamma$ -pyrone, is a selective and reversible Lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 51 $\mu$ M in a HRP-coupled enzymatic assay. Namoline impairs LSD1 demethylase activity and blocks cell proliferation. Namoline has the potential for androgen-dependent prostate cancer research <sup>[1]</sup> .
In Vitro	Namoline (50 $\mu$ M; 24, 48, 72 hours) reduces androgen-induced proliferation of LNCaP cells <sup>[1]</sup> . Namoline (50 $\mu$ M) specifically impairs AR agonist R1881-induced (1 nM) demethylation of H3K9me1 and H3K9me2 in LNCaP cells <sup>[1]</sup> . Namoline (50 $\mu$ M) does not affect the enzymatic activities of MAOs under these conditions <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Namoline (0.02 mg;ip; daily) severely blunts xenograft tumor growth in nude mice with LNCaP cells <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Dominica Willmann, et al. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer. 2012 Dec 1;131(11):2704-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA